Your browser doesn't support javascript.
loading
Establishment of a flow cytometry screening method for patients with glucose transporter 1 deficiency syndrome.
Nakamura, Sachie; Ito, Yasushi; Hayakawa, Hiroko; Aoki, Shiho; Yamagata, Takanori; Osaka, Hitoshi.
Afiliación
  • Nakamura S; Department of Pediatrics, Jichi Medical University, Tochigi, Japan.
  • Ito Y; Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan.
  • Hayakawa H; Research Department of Pediatric and Maternal Health, Aiiku Research Institute, Aiiku Maternal & Child Health Center, Tokyo, Japan.
  • Aoki S; Department of Biochemistry, Jichi Medical University, Tochigi, Japan.
  • Yamagata T; Department of Pediatrics, Jichi Medical University, Tochigi, Japan.
  • Osaka H; Department of Pediatrics, Jichi Medical University, Tochigi, Japan.
Mol Genet Metab Rep ; 34: 100954, 2023 Mar.
Article en En | MEDLINE | ID: mdl-36618999
ABSTRACT

Objective:

We assessed the usefulness of flow cytometry as a functional assay to measure glucose transporter 1 (GLUT1) levels on the surface of red blood cells (RBCs) from Japanese patients with glucose transporter 1 deficiency syndrome (Glut1DS).

Methods:

We recruited 13 genetically confirmed Glut1DS patients with a solute carrier family 2 member 1 (SLC2A1) mutation (eight missense, one frameshift, two nonsense, and two deletion) and one clinically suspected Glut1DS-like patient without an SLC2A1 mutation, and collected whole blood with informed consent. We stained pelleted RBCs (1 µL) from the patients with a Glut1.RBD ligand and anti-glycophorin A antibody, which recognizes a human RBC membrane protein, and analyzed the cells using flow cytometry.

Results:

Relative GLUT1 levels quantified by flow cytometry in 11 of 13 patients with definite Glut1DS were 90% below those of healthy controls. Relative GLUT1 levels were not reduced in two of 13 Glut1DS patients who had a missense mutation and no intellectual disability and one Glut1DS-like patient without an SLC2A1 mutation. Relative GLUT1 levels were significantly reduced in Glut1DS patients with an SLC2A1 mutation, more severe intellectual disability, and spasticity.

Conclusions:

This method to detect GLUT1 levels on RBCs is simple and appears to be an appropriate screening assay to identify severe Glut1DS patients in the early stage before the development of irreversible neurologic damage caused by chronic hypoglycorrhachia.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Mol Genet Metab Rep Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Mol Genet Metab Rep Año: 2023 Tipo del documento: Article País de afiliación: Japón